Sean George , , Ph.D. , , Chief Executive Officer

Sean is chief executive officer of Invitae, whose mission is to bring genetic information into mainstream medicine. Prior to his CEO position, he served as Invitae’s president and chief operating officer. Sean was a co-founder and CEO of Locus Development, an early stage genetic analysis startup that later merged with Invitae. Prior to co-founding Locus, he served as COO at Navigenics, an early leader in personalized medicine. Previously, he has also served as SVP of Marketing and SVP, Life Science Business at Affymetrix as well as VP, Labeling and Detection Business at Invitrogen. In the past, he has also worked at McKinsey & Co. and Molecular Probes. Dr. George holds a B.S. in Molecular Genetics from UCLA, an M.S. in Molecular Biology from UC Santa Barbara, and a Ph.D. in Molecular Genetics from UC Santa Cruz.

Randy Scott , , Ph.D. , , Executive Chairman

Randy is executive chairman of Invitae. Prior to this position, Randy served as chief executive officer. Prior to co-founding Invitae, Randy served as Genomic Health's Chief Executive Officer from 2000 until 2009 and Executive Chairman until 2012. Under Randy's leadership, Genomic Health developed and launched two revolutionary cancer diagnostics tests. At Incyte, Randy served in various roles from 1991 through 2000, including Chairman of the Board, President and Chief Scientific Officer. Randy holds a B.S. in Chemistry from Emporia State University and a Ph.D. in Biochemistry from the University of Kansas. Randy is a prominent thought leader in the genomics and sequencing space and is the author of more than 40 publications, 20 patents, and is the recipient of numerous awards, which highlight his leadership in the personalized medicine space.

Swaroop Aradhya , , Ph.D. , , Medical Affairs

Dr. Aradhya is a board-certified molecular geneticist and cytogeneticist who has helped shape professional practices and technology applications in clinical genetic testing over the past 15 years. He joined Invitae to help bring genetics into mainstream medicine by innovating laboratory technologies, fostering advances in evidence-based clinical standards, and building mechanisms to empower individuals globally to access their genetic information. Before Invitae, Swaroop was VP and senior laboratory director for Neurogenetics and Clinical Microarrays at GeneDx. He completed medical genetics training in 2007 at Stanford University and received his Ph.D. in molecular and human genetics in 2001 at Baylor College of Medicine. Over the course of his career, he has participated in the international Human Genome Project to sequence the X chromosome and helped characterize several genetic disorders. He is currently a ClinGen investigator, serves on the Board of Directors of the American Board of Medical Genetics and Genomics, and is an adjunct clinical associate professor at Stanford University School of Medicine.

Lee Bendekgey , , , Chief Financial Officer

Lee leads Invitae’s finance, administrative, and operations teams. His goal is to help make Invitae a trusted partner for patients, healthcare providers, payers, and investors. He has led finance, administrative, and operations functions at public and private genomics and biotechnology companies, including Incyte, Nuvelo, and DNAnexus. Lee earned his B.A. from Kalamazoo College and his law degree from Stanford Law School.

Tom Brida , , , General Counsel

Tom leads the legal team at Invitae and has more than 13 years of legal experience in the life science and diagnostic industries. He has a broad-based legal background and has advised both public and private multinational companies on transactional​​ and corporate matters. Prior to joining Invitae, he was Associate General Counsel at Bio-Rad Laboratories and an associate in Orrick's corporate and technology group. He earned his B.A. from Stanford University and his law degree from U.C. Berkeley School of Law.

Michele Cargill , , Ph.D. , , Program Management

Michele serves as a member of Invitae’s strategy team. She has more than 17 years of experience as a human geneticist in both industry and academia, with a primary interest in discovering the genes that contribute to human disease and translating that information for patients and medical care professionals. Prior to co-founding Locus Development, Michele served as vice president of genetics at Navigenics and associate director of genomic collaborations at Affymetrix. She also served as senior staff scientist at Celera Diagnostics and scientific program manager at Celera Genomics. She trained under the tutelage of David Botstein at Stanford Medical School, where she earned her Ph.D. in genetics, and Eric Lander at the Whitehead Institute, where she did her postdoctoral training.

Patty Dumond , , , Chief Accounting Officer

Patty brings more than 20 years of finance expertise to Invitae with broad experience in all aspects of accounting, auditing, and financial management. At Invitae, she has built a collaborative financial team and leads strategic efforts to ensure compliance and transparency. Patty thrives at fast-growing companies, being involved in the early stages and public offerings of both Genomic Health and Rigel Pharmaceuticals prior to joining the Invitae team. She earned her B.S. in finance with a minor in accounting from California State University - Sacramento.

Alex Furman , , , Talent Operations

Alex was one of the co-founders of Locus Development (which later merged with Invitae) and leads Invitae’s talent operations team. Prior to Invitae, he led the software engineering effort at Navigenics and before that, spent many years developing automated trading systems and financial planning software. A born-and-bred programmer, Alex grew up playing with computers that took up entire rooms and were orders of magnitude less powerful than the smartphone he now carries in his pocket.

Robert Nussbaum , , M.D. , , Chief Medical Officer

Dr. Nussbaum has served as Invitae’s Chief Medical Officer since August 2015. Prior to joining Invitae, he was chief of the Division of Genomic Medicine at UCSF Health where he also held leadership roles in the Cancer Genetics and Prevention Program beginning in January 2009 and the Program in Cardiovascular Genetics beginning in July 2007. From April 2006 to August 2015, he served as a member of the UCSF Institute for Human Genetics. Prior to joining UCSF Health, Dr. Nussbaum was chief of the Genetic Disease Research Branch of the National Human Genome Research Institute, one of the National Institutes of Health, from 1994 to 2006. He is a member of the Institute of Medicine and a fellow at the American Academy of Arts and Sciences. Dr. Nussbaum is a board-certified internist and medical geneticist who holds a B.S. in Applied Mathematics from Harvard College and an M.D. from Harvard Medical School in the Harvard-MIT joint program in Health Sciences and Technology. He completed his residency in internal medicine at Barnes-Jewish Hospital and a fellowship in medical genetics at the Baylor College of Medicine.

Eric Olivares , , Ph.D. , , Clinical Operations and Assay Development

Eric leads Invitae's sample processing, clinical sign out, and assay development teams. Eric has developed next-generation sequencing workflows for over a decade at both tool suppliers and instrument manufacturers. He joined Locus Development in 2011 to lead the molecular biology R&D group, which subsequently merged with Invitae. His goal is to continue to develop the highest quality, most robust, and lowest cost genetic tests in the world. Eric holds a Ph.D. in Genetics from Stanford University and a B.S. in Genetics from University of California, Davis.

Jon Sorenson , , Ph.D. , , Technology and Engineering

Jon brings 16 years of sequencing analysis and software experience to Invitae, having devoted more than a decade to next-generation sequencing software development and analysis. Prior to joining Invitae, he built and led the bioinformatics and analysis software teams at Pacific Biosciences and led the software development for the first generation of ABI SOLiD at Applied Biosystems. He is one of the few people in the world to have analyzed sequencing data from seven different DNA sequencing technologies, old and new. His early days in human genetic variation were spent examining Sanger sequencing traces, writing algorithms and constructing the SeqScape, VariantSEQr, and Variant Reporter resequencing platforms at Applied Biosystems. Jon is a co-author on 23 publications and 12 patents. He holds a Ph.D. in Chemistry from the University of California at Berkeley, an M.Phil. in Theoretical Chemistry from the University of Cambridge, and a B.S. in both Mathematics and Chemistry from Harvey Mudd College.

Katherine Stueland , , , Chief Commercial Officer

Katherine leads Invitae's commercial organization, overseeing sales, marketing, managed care, international, pharma/biotech collaborations, communications, investor relations, public relations, and advocacy initiatives. Prior to joining the team at Invitae, Katherine worked with private and publicly traded biotech companies, including serving as vice president of communications and investor relations at Dendreon Corporation, the first company to bring an immuno-oncology product to market. Katherine started her career in her hometown of Chicago, where she worked with a portfolio of biotechnology and pharmaceutical companies, including TAP (Takeda/Abbott) Pharmaceuticals. Katherine serves on the board of The Rivkin Center for Ovarian Cancer and graduated from Miami University in Ohio.
NYSE: NVTA 10.53 -0.02 -0.19% Volume: 245,188 20 minute delay March 28, 2017

Investor Toolkit

Feature Presentation

Email Alerts

Sign up to receive Invitae financial information by email.
Email Address: *

Enter the code shown above.

Investor Contact

1400 16th St.
San Francisco, CA, 94103